Table 1 Characteristics of the RNA-positive individuals who underwent antiviral therapy

Age(years)

 < 40

8

36.364

14

63.636

10.453

Ref

Ref

 40–59

31

30.392

71

69.608

0.005

2.855 (1.389–5.866)

9.135 (1.815–45.986)

 ≥ 60

13

13.265

85

86.735

3.736 (1.312–10.640)

9.999 (2.878–34.737)

Sex

 Male

33

23.239

109

76.761

0.007

Ref

Ref

 Female

19

23.75

61

76.25

0.931

0.972 (0.510–1.854)

0.807 (0.329–1.980)

Residence

 Fuzhou

36

29.752

85

70.248

5.939

Ref

Ref

 Other cities

16

15.842

85

84.158

0.015

2.250 (1.162–4.359)

3.641 (1.346–9.851)

Insurance

 Employee health insurance

39

28.676

97

71.324

5.401

Ref

Ref

 Urban residents’ basic medical insurance

13

15.116

73

84.884

0.020

2.258 (1.124–4.534)

3.742 (1.388–10.090)

HCV multi-disciplinary cooperation in the hospital

 2016.1–2019.9

21

12.426

148

87.574

47.731

Ref

Ref

 2019.10–2022.12

31

58.491

22

41.509

 < 0.001

0.101 (0.049–0.205)

0.024 (0.007–0.074)

Hepatic status

 No fibrosis

37

21.143

138

78.857

2.397

Ref

Ref

 Hepatic fibrosis

15

31.915

32

68.085

0.122

0.572 (0.280–1.166)

0.109 (0.034–0.352)

Tumours or other serious diseases

 Without

42

27.451

111

72.549

4.452

Ref

Ref

 With

10

14.492

59

85.507

0.035

2.232 (1.046–4.766)

5.533 (1.597–19.172)